biotech / news / / NDTV.com
Lormalzi is a once-monthly amyloid plaque-targeting therapy approved for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Eli Lilly launched Lormalzi (donanemab), India's first once-monthly amyloid plaque-targeting Alzheimer's therapy.
KEY POINTS
- Lormalzi costs Rs91,688 per 350 mg vial and is approved for early Alzheimer's with confirmed amyloid pathology.
- Blood-based biomarker tests like pTau217 and beta-amyloid 1-42 now enable over 90% accuracy for amyloid detection in India.
- In India, Lormalzi treatment typically lasts 18 months due to limited access to amyloid PET imaging.
COMPANIES
Summarized by Newsio from NDTV.com. How we summarize →